02
Mar

Memorial Sloan Kettering Cancer Center picked up the FDA’s coveted breakthrough-therapy designation for a promising T cell therapy, working with partner Atara Biotherapeutics to get it on the market for patients with complications tied to bone marrow transplants.

…read more

Source: MSK and Atara snag an FDA ‘breakthrough’ tag for T cell project

    

0 No comments